Caspofungin

Therapeutic

For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Structural features

SMILES

CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O

Sequence

XXTXXXX

Molar mass

1093.331 g/mol

Constitutional members:

8

Natural amino acids

1

D-Amino acids

0

N-terminus

tridecanoyl

C-terminus

cycle

Cyclic

yes

Members/cycle

6

Bond to form cycle

head-to-side chain (3-OH-Hyp-propionic acid)

Lipidation

yes

Glycosylation

no

Route of administration

IV

Terminal half-life

9-11 hours

Protein binding

0.97

Absorption and Bioavailability

Caspofungin has negligible bioavailability when administered orally; therefore parenteral dosing is indicated.

References